Recently, Ustekinumab,a monoclonal therapeutic antibody directed against interleukin-12 and interleukin-23 (both associated to IFNG signaling pathway) has been identified as a potential candidate to treat AD [67]. Here, IL37 is linked to Alzheimer disease.